Programmable quantum simulators

Quantum computing solutions

AI and quantum physics driven drug discovery

Customer engagement management software

Makeup, skin care & beauty collection

AI app publisher

Online payment platform

Chez Breek, nous aidons les entreprises du BTP à transformer leur documentation en intelligence exploitable grâce à l'IA.

La construction représente près de 10% du PIB mondial, mais c'est aussi l'un des secteurs les moins digitalisés. Chaque projet génère des centaines de pages de documents techniques, de plans, de spécifications. Toute l'information nécessaire est là, mais noyée dans la masse. Retrouver une donnée critique prend des heures, les erreurs d'interprétation coûtent cher, les opportunités sont manquées faute de temps.

Notre solution permet aux entreprises d'analyser, d'extraire et d'exploiter instantanément les informations critiques de leur documentation. L'objectif : participer à plus de projets, réduire les erreurs, gagner du temps et alléger la charge mentale des équipes.

Bipolar disorder affects 1.6 million people in France, with a 95% relapse rate over 10 years.

6th cause of disability worldwide (WHO).

8 to 10 years: the average delay before diagnosis.

At Leopa, we are developing the first digital medical device (Software as a Medical Device) to help patients stabilize their mood and space out relapses. Our early users are already telling us how much the app helps them on a daily basis.

Our approach is rooted in precision psychiatry, combining artificial intelligence with clinical expertise. We are starting with bipolar disorder before expanding our approach to other chronic psychiatric conditions. The shift towards patient-led precision psychiatry is happening right now and we want to be the ones driving it.

Incubated at Télécom Paris and based in the heart of Paris, we are moving fast: the team will grow significantly in the coming months, and our roadmap is packed.

WHO ARE WE ?

We are a small, focused, and ambitious team. Three founders (Mohand, Hanthony, Margot), an active community of pilot patients tested in partnership with Argos 2001 (France's leading bipolar patient association), a strong scientific advisory board and a roadmap we have the conviction to execute.

The early signal is strong:

• Our pilot cohort shows around 45% retention**, well above digital therapeutics industry benchmarks.
• Our Class I medical device is coming to market in the coming months : a critical milestone that very few digital health startups in mental health reach.
• We are Laureat France 2030 since July 2026